Danaher Corp.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2358511028
USD
227.13
-1.33 (-0.58%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

4.09 M

Shareholding (Mar 2025)

FII

20.97%

Held by 662 FIIs

DII

44.32%

Held by 97 DIIs

Promoter

0.06%

How big is Danaher Corp.?

22-Jun-2025

As of Jun 18, Danaher Corp. has a market capitalization of $167.63 billion, with recent net sales of $23.82 billion and a net profit of $3.77 billion.

Market Cap: As of Jun 18, Danaher Corp. has a market capitalization of 167,634.35 million, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Danaher Corp. reported net sales of 23,820.00 million and a net profit of 3,765.00 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 49,543.00 million and total assets of 77,542.00 million.

Read More

What does Danaher Corp. do?

22-Jun-2025

Danaher Corporation designs and manufactures products and services in the Pharmaceuticals & Biotechnology industry, with recent net sales of $5.74 billion and a market cap of approximately $167.63 billion. Key metrics include a P/E ratio of 40.00 and a dividend yield of 0.49%.

Overview:<BR>Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services in the Pharmaceuticals & Biotechnology industry, with a market capitalization in the large-cap bracket.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 5,741 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 954 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 167,634.35 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 40.00 <BR>Dividend Yield: 0.49% <BR>Debt Equity: 0.31 <BR>Return on Equity: 8.34% <BR>Price to Book: 3.30 <BR><BR>Contact Details:<BR>Address: 2200 Pennsylvania Ave NW Ste 800w, WASHINGTON DC: 20037-1731 <BR>Tel: 1 202 8280850 <BR>Fax: 1 202 8280860 <BR>Website: https://www.danaher.com/

Read More

Should I buy, sell or hold Danaher Corp.?

22-Jun-2025

Who are in the management team of Danaher Corp.?

22-Jun-2025

As of March 2022, the management team of Danaher Corp. includes Steven Rales (Chairman), Rainer Blair (CEO), Linda Hefner Filler (Lead Independent Director), Mitchell Rales, Teri List-Stoll, Walter Lohr, and Jessica Mega (all Independent Directors).

As of March 2022, the management team of Danaher Corp. includes the following individuals:<BR><BR>- Mr. Steven Rales, Chairman of the Board<BR>- Mr. Rainer Blair, President, Chief Executive Officer, Director<BR>- Ms. Linda Hefner Filler, Lead Independent Director<BR>- Mr. Mitchell Rales, Director<BR>- Ms. Teri List-Stoll, Independent Director<BR>- Mr. Walter Lohr, Independent Director<BR>- Dr. Jessica Mega, Independent Director

Read More

Is Danaher Corp. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Danaher Corp. is considered very expensive with a P/E ratio of 40 and has underperformed the S&P 500, showing a year-to-date return of -8.93% compared to the index's 13.30%.

As of 17 October 2025, the valuation grade for Danaher Corp. has moved from expensive to very expensive, indicating a significant concern regarding its current valuation. The company is overvalued based on its key metrics, which include a P/E ratio of 40, a Price to Book Value of 3.30, and an EV to EBITDA of 24.40. In comparison, Abbott Laboratories, which is considered fairly valued, has a P/E ratio of 18.36, while Thermo Fisher Scientific, also fairly valued, has a P/E ratio of 30.06.<BR><BR>The stock has underperformed against the S&P 500, with a year-to-date return of -8.93% compared to the S&P 500's 13.30%, and a one-year return of -23.13% versus the S&P 500's 14.08%. This trend reinforces the notion that Danaher Corp. is not only overvalued but also struggling to deliver returns relative to the broader market.

Read More

Is Danaher Corp. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Danaher Corp. shows a mildly bullish technical trend with positive momentum indicators, but it has underperformed the S&P 500 significantly, warranting cautious consideration.

As of 31 October 2025, the technical trend for Danaher Corp. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. The daily moving averages are also bullish, supporting the upward trend. However, the monthly Bollinger Bands are bearish, which suggests some caution. The KST shows a bullish stance on the weekly timeframe but is bearish monthly, indicating mixed signals. Overall, the Dow Theory indicates a mildly bullish trend on the weekly basis with no trend monthly.<BR><BR>In terms of performance, Danaher has underperformed the S&P 500 across multiple periods, with a year-to-date return of -6.85% compared to the S&P 500's 16.30%, and a one-year return of -13.69% versus 19.89% for the benchmark. This underperformance highlights the need for careful consideration despite the current mildly bullish technical stance.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 25.63

 
2

Flat results in Jun 25

3

With ROCE of 7.77%, it has a expensive valuation with a 2.76 Enterprise value to Capital Employed

4

Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks

 
5

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 170,177 Million (Large Cap)

stock-summary
P/E

40.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.50%

stock-summary
Debt Equity

0.30

stock-summary
Return on Equity

8.10%

stock-summary
Price to Book

3.25

Revenue and Profits:
Net Sales:
5,936 Million
(Quarterly Results - Jun 2025)
Net Profit:
555 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
14.12%
0%
14.12%
6 Months
17.64%
0%
17.64%
1 Year
-3.86%
0%
-3.86%
2 Years
2.25%
0%
2.25%
3 Years
-17.18%
0%
-17.18%
4 Years
-27.42%
0%
-27.42%
5 Years
1.2%
0%
1.2%

Danaher Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
4.20%
EBIT Growth (5y)
9.15%
EBIT to Interest (avg)
25.63
Debt to EBITDA (avg)
1.70
Net Debt to Equity (avg)
0.31
Sales to Capital Employed (avg)
0.37
Tax Ratio
16.41%
Dividend Payout Ratio
20.42%
Pledged Shares
0
Institutional Holding
83.39%
ROCE (avg)
10.41%
ROE (avg)
11.52%
Valuation key factors
Factor
Value
P/E Ratio
40
Industry P/E
Price to Book Value
3.30
EV to EBIT
35.55
EV to EBITDA
24.40
EV to Capital Employed
2.76
EV to Sales
7.70
PEG Ratio
NA
Dividend Yield
0.49%
ROCE (Latest)
7.77%
ROE (Latest)
8.34%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 244 Schemes (34.6%)

Foreign Institutions

Held by 662 Foreign Institutions (20.97%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 3.40% vs -12.19% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -41.82% vs -12.15% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,936.00",
          "val2": "5,741.00",
          "chgp": "3.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,803.00",
          "val2": "1,880.00",
          "chgp": "-4.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "71.00",
          "val2": "72.00",
          "chgp": "-1.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-470.00",
          "val2": "-39.00",
          "chgp": "-1,105.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "555.00",
          "val2": "954.00",
          "chgp": "-41.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "200.80%",
          "val2": "224.50%",
          "chgp": "-2.37%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -0.06% vs -10.33% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -7.63% vs -33.30% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "23,875.00",
          "val2": "23,890.00",
          "chgp": "-0.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7,536.00",
          "val2": "7,445.00",
          "chgp": "1.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "278.00",
          "val2": "289.00",
          "chgp": "-3.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-534.00",
          "val2": "-348.00",
          "chgp": "-53.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3,899.00",
          "val2": "4,221.00",
          "chgp": "-7.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "217.10%",
          "val2": "221.00%",
          "chgp": "-0.39%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
5,936.00
5,741.00
3.40%
Operating Profit (PBDIT) excl Other Income
1,803.00
1,880.00
-4.10%
Interest
71.00
72.00
-1.39%
Exceptional Items
-470.00
-39.00
-1,105.13%
Consolidate Net Profit
555.00
954.00
-41.82%
Operating Profit Margin (Excl OI)
200.80%
224.50%
-2.37%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 3.40% vs -12.19% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -41.82% vs -12.15% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
23,875.00
23,890.00
-0.06%
Operating Profit (PBDIT) excl Other Income
7,536.00
7,445.00
1.22%
Interest
278.00
289.00
-3.81%
Exceptional Items
-534.00
-348.00
-53.45%
Consolidate Net Profit
3,899.00
4,221.00
-7.63%
Operating Profit Margin (Excl OI)
217.10%
221.00%
-0.39%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -0.06% vs -10.33% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -7.63% vs -33.30% in Dec 2023

stock-summaryCompany CV
About Danaher Corp. stock-summary
stock-summary
Danaher Corp.
Pharmaceuticals & Biotechnology
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through three segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification. Danaher's research and development, manufacturing, sales, distribution, service and administrative facilities were located in over 60 countries.
Company Coordinates stock-summary
Company Details
2200 Pennsylvania Ave NW Ste 800w , WASHINGTON DC : 20037-1731
stock-summary
Tel: 1 202 8280850
stock-summary
Registrar Details